Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting
Authors:
- Deepak SundriyalDSDeepak Sundriyal
- Sai PrasathSPSai Prasath
- Harsha S. PrakashHPHarsha S. Prakash
- Anusha Mruthyunjaya SwamyASAnusha Mruthyunjaya Swamy
- Karthik JayalingappaKJKarthik Jayalingappa
- Mayank KapoorMKMayank Kapoor
- Mahesh KoulagiMKMahesh Koulagi
- Deepa JosephDJDeepa Joseph
- Sweety GuptaSGSweety Gupta
- Parmod KumarPKParmod Kumar
- Ujjawal ShriwastavUSUjjawal Shriwastav
- Amit SehrawatASAmit Sehrawat
Open Access
- 1 August 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Abstract
PURPOSE: Muscle-invasive bladder carcinoma (MIBC) poses major treatment challenges in low- and middle-income countries because of logistical and socioeconomic barriers limiting neoadjuvant chemotherapy (NAC) delivery. While dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) improves pathologic response and survival over gemcitabine-cisplatin, its multiday schedule reduces practicality. Accelerated MVAC (AMVAC), a single-day outpatient regimen, may offer a feasible alternative. This study evaluated the feasibility and safety of AMVAC in Indian patients with MIBC. METHODS: We conducted a single-arm feasibility study at the All India Institute of Medical Sciences, Rishikesh, India, between December 2021 and November 2024. Adults with stage II-III MIBC and cisplatin eligibility received 3-4 cycles of single-day AMVAC with pegfilgrastim support before radical cystectomy. Feasibility was defined as completion of ≥3 or 4 cycles within protocol-specified timeframes. Toxicities were graded using CTCAE v5.0, and outcomes were analyzed descriptively. RESULTS: Sixty patients were enrolled (mean age 55.2 ± 11.2 years; 90% male); 55 received neoadjuvant, and five adjuvant therapy. The mean number of chemotherapy cycles delivered was 3.87 ± 0.85. Feasibility outcomes were favorable, with 91.6% completing three and 76.6% completing four cycles within protocol timelines. Dose reductions for grade ≥3 toxicities were required in 13 patients (21.7%), whereas four patients discontinued treatment because of reduced creatinine clearance. Grade 3 adverse events occurred in 38.3%, most commonly anemia (16.7%), fatigue, and mucositis (13.3% each). Among neoadjuvant recipients undergoing cystectomy (n = 40), pathologic complete response (PCR) was achieved in 32.5% and pathologic downstaging was achieved in 55%. CONCLUSION: Single-day AMVAC is a feasible and tolerable NAC regimen in a resource-constrained setting, with encouraging PCR and manageable toxicity.Keywords
This publication has 12 references indexed in Scilit:
- Cancer Incidence and Mortality Across 43 Cancer Registries in IndiaJAMA Network Open, 2025
- Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancerDiscover Oncology, 2025
- Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income CountryJCO Global Oncology, 2024
- Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyThe Lancet Oncology, 2023
- Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus MethodIndian Journal of Medical and Paediatric Oncology, 2023
- Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical CystectomyJournal of Urology, 2018
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and ToxicityJournal of Clinical Oncology, 2014
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker CorrelatesJournal of Clinical Oncology, 2014
- Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladderCancer, 2012
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011